Back to Stakeholders
Research, Drug Development & ManufacturingLead program: Phase I

Elkedonia

1 Drug Candidate

Elkedonia is a French neuroplastogen biotech developing novel small molecules targeting the Elk-1 transcription factor, a key regulator of neuroplasticity within neuronal cells. Backed by €11 million in funding, the company is advancing clinical research into next-generation antidepressants that promote neuroplasticity without the adverse effects of traditional treatments, with CEO Delphine Charvin leading the programme.

Drug Pipeline

1

ELK-1 Neuroplastogen Program

Phase I
Depressive Disorders

Novel small molecules targeting Elk-1 transcription factor to promote neuroplasticity in depression treatment.

Quick Facts

Type
Private Biotech
Lead Stage
Phase I
Website
Visit